NYSE:GSK - GlaxoSmithKline Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$41.04 -0.23 (-0.56 %)
(As of 06/20/2018 04:56 AM ET)
Previous Close$41.27
Today's Range$40.6550 - $41.06
52-Week Range$34.52 - $44.44
Volume1.66 million shs
Average Volume3.43 million shs
Market Capitalization$102.75 billion
P/E Ratio14.25
Dividend Yield5.07%
GlaxoSmithKline logoGlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. It has a discovery collaboration agreement with Kymera Therapeutics LLC. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity Ratio3.90
Current Ratio0.61
Quick Ratio0.40


Trailing P/E Ratio14.25
Forward P/E Ratio14.45
P/E Growth2.21

Sales & Book Value

Annual Sales$38.89 billion
Price / Sales2.62
Cash Flow$3.8035 per share
Price / Cash10.79
Book Value$1.81 per share
Price / Book22.67


EPS (Most Recent Fiscal Year)$2.88
Net Income$1.97 billion
Net Margins3.50%
Return on Equity144.84%
Return on Assets10.29%


Outstanding Shares2,479,430,000

GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline announced a quarterly dividend on Thursday, April 26th. Shareholders of record on Friday, May 11th will be paid a dividend of $0.5298 per share on Thursday, July 12th. This represents a $2.12 annualized dividend and a yield of 5.16%. The ex-dividend date is Thursday, May 10th. View GlaxoSmithKline's Dividend History.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) announced its quarterly earnings results on Wednesday, April, 25th. The pharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.70 by $0.02. The pharmaceutical company had revenue of $10.04 billion for the quarter, compared to the consensus estimate of $10.26 billion. GlaxoSmithKline had a return on equity of 144.84% and a net margin of 3.50%. View GlaxoSmithKline's Earnings History.

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for GlaxoSmithKline.

What price target have analysts set for GSK?

13 analysts have issued 12 month price objectives for GlaxoSmithKline's shares. Their predictions range from $35.85 to $40.00. On average, they anticipate GlaxoSmithKline's share price to reach $38.6167 in the next year. View Analyst Ratings for GlaxoSmithKline.

Are investors shorting GlaxoSmithKline?

GlaxoSmithKline saw a drop in short interest in May. As of May 31st, there was short interest totalling 8,497,397 shares, a drop of 27.2% from the May 15th total of 11,675,520 shares. Based on an average daily trading volume, of 2,406,543 shares, the short-interest ratio is currently 3.5 days.

Who are some of GlaxoSmithKline's key competitors?

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the folowing people:
  • Ms. Emma Walmsley, Chief Exec. Officer & Director (Age 48)
  • Mr. Simon P. Dingemans, Chief Financial Officer & Exec. Director (Age 54)
  • Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 55)
  • Ms. Karenann K. Terrell, Chief Digital & Technology Officer (Age 56)
  • Mr. Daniel E. Troy, Sr. VP and Gen. Counsel

Has GlaxoSmithKline been receiving favorable news coverage?

Headlines about GSK stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. GlaxoSmithKline earned a news sentiment score of 0.24 on Accern's scale. They also assigned news coverage about the pharmaceutical company an impact score of 46.50 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are GlaxoSmithKline's major shareholders?

GlaxoSmithKline's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Royal Bank of Canada (0.86%), Fisher Asset Management LLC (0.54%), Federated Investors Inc. PA (0.17%), Northern Trust Corp (0.13%), Equity Investment Corp (0.13%) and Schafer Cullen Capital Management Inc. (0.08%). View Institutional Ownership Trends for GlaxoSmithKline.

Which institutional investors are selling GlaxoSmithKline stock?

GSK stock was sold by a variety of institutional investors in the last quarter, including Royal Bank of Canada, Millennium Management LLC, Federated Investors Inc. PA, SeaTown Holdings Pte. Ltd., PVG Asset Management Corp, Envestnet Asset Management Inc., SG Americas Securities LLC and Thrivent Financial for Lutherans. View Insider Buying and Selling for GlaxoSmithKline.

Which institutional investors are buying GlaxoSmithKline stock?

GSK stock was purchased by a variety of institutional investors in the last quarter, including Equity Investment Corp, Schafer Cullen Capital Management Inc., Fisher Asset Management LLC, BlackRock Inc., LPL Financial LLC, CIBC World Markets Inc., Northern Trust Corp and Summit Trail Advisors LLC. View Insider Buying and Selling for GlaxoSmithKline.

How do I buy shares of GlaxoSmithKline?

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately $41.04.

How big of a company is GlaxoSmithKline?

GlaxoSmithKline has a market capitalization of $102.75 billion and generates $38.89 billion in revenue each year. The pharmaceutical company earns $1.97 billion in net income (profit) each year or $2.88 on an earnings per share basis. GlaxoSmithKline employs 99,827 workers across the globe.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]

MarketBeat Community Rating for GlaxoSmithKline (GSK)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  389 (Vote Outperform)
Underperform Votes:  727 (Vote Underperform)
Total Votes:  1,116
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe GSK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.